791 related articles for article (PubMed ID: 24918198)
21. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
22. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
Gilligan PJ
Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
[TBL] [Abstract][Full Text] [Related]
24. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Rudenko IN; Chia R; Cookson MR
BMC Med; 2012 Feb; 10():20. PubMed ID: 22361010
[TBL] [Abstract][Full Text] [Related]
25. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
26. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
27. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
29. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
West AB
Mov Disord; 2015 Feb; 30(2):180-9. PubMed ID: 25448543
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
31. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
[TBL] [Abstract][Full Text] [Related]
32. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
33. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
34. I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule.
Ohta E; Katayama Y; Kawakami F; Yamamoto M; Tajima K; Maekawa T; Iida N; Hattori S; Obata F
Biochem Biophys Res Commun; 2009 Dec; 390(3):710-5. PubMed ID: 19833102
[TBL] [Abstract][Full Text] [Related]
35. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
36. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
37. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
39. Kinases as targets for Parkinson's disease: from genetics to therapy.
Vancraenenbroeck R; Lobbestael E; Maeyer MD; Baekelandt V; Taymans JM
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):724-40. PubMed ID: 21838679
[TBL] [Abstract][Full Text] [Related]
40. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease.
Lopez de Maturana R; Aguila JC; Sousa A; Vazquez N; Del Rio P; Aiastui A; Gorostidi A; Lopez de Munain A; Sanchez-Pernaute R
Neurobiol Aging; 2014 May; 35(5):1116-24. PubMed ID: 24360742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
